Core Viewpoint - The announcement highlights that Shandong Huate Dain Health Co., Ltd.'s subsidiary, Dain Pharmaceutical, has received a drug registration certificate for a medication aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-17, which is expected to enhance the company's product pipeline and competitive position in the pediatric health sector [1][2]. Group 1: Drug Registration Certificate Details - Dain Pharmaceutical has obtained the drug registration certificate for Clonidine Hydrochloride Extended-Release Tablets, with the certificate number 2025S03966 [1]. - The medication is intended for the treatment of ADHD in children and adolescents aged 6-17, either alone or as an adjunct to central nervous system stimulants [1]. Group 2: Impact on the Company - The acquisition of the drug registration certificate is anticipated to enrich the company's product line in the ADHD treatment area, supporting the realization of its strategic development and enhancing its competitiveness [2]. - The introduction of this medication is expected to positively impact the company's commitment to children's health and its performance [2].

Core Viewpoint - The company announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Clonidine Hydrochloride Extended-Release Tablets, specifically for the treatment of ADHD in children aged 6-17 years [2] Group 1 - The approved product is Clonidine Hydrochloride Extended-Release Tablets with a specification of 0.1mg [2] - The approval number for the product is Guoyao Zhunzi H20256411, and it is valid until December 29, 2030 [2]

Core Viewpoint - The company Huate Dain has received a drug registration certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years [1] Group 1 - The drug is intended for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]

Core Viewpoint - Huatai Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received a Drug Registration Certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, which is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The product is specifically used as a standalone or adjunctive treatment with central nervous system stimulants for ADHD [1]

Core Viewpoint - The company announced that its subsidiary, Shandong Dain Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The drug is indicated for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]

Group 1 - The core point of the article is that Huate Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets [1] Group 2 - The drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years, either as a standalone treatment or as an adjunct to central nervous system stimulants [1]

证券代码：000915 证券简称：华特达因 公告编号：2026-001 山东华特达因健康股份有限公司 | 药品名称 | | | 盐酸可乐定缓释片 | | | --- | --- | --- | --- | --- | | 主要成分 | | | 盐酸可乐定 | | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 规格 | 0.1mg | | 注册分类 | 化学药品 3 类 | | 药品注册标准编号 | YBH32192025 | | 药品有效期 | 36 个月 | | 包装规格 | 1 瓶/盒 | | 处方药/非处方药 | 处方药 | | 上市许可持有人 | | | 山东达因海洋生物制药股份有限公司 | | | 生产企业 | | | 山东达因海洋生物制药股份有限公司 | | | 药品批准文号 | 国药准字 | H20256411 | 药品批准文号有效期 | 至 2030 年 12 月 29 日 | 一、药品注册证书基本情况 二、药品的其他相关情况说明 本品用于单独或辅助中枢兴奋药治疗 6-17 岁儿童和青少年的注 意缺陷多动障碍（ADHD）。 三、获得药品注册证书对公司的影响及风险提示 ...

Group 1 - The company held its fifth temporary board meeting of the 11th session on December 22, 2025, with all 9 directors present, confirming compliance with legal and regulatory requirements [2] - The board approved several proposals unanimously, including amendments to the General Manager's Office Meeting Rules, the Board Secretary Work System, and the Information Disclosure Management System [3][4] - The board also approved the establishment of a temporary and exemption management system for information disclosure and agreed to extend the operational period of the Everbright Wealth Medical Fund until January 30, 2028, along with signing a supplementary agreement [4]

每经AI快讯，华特达因12月22日晚间发布公告称，公司第十一届2025年第五次董事会临时会议于2025 年12月22日在公司会议室召开。会议审议了《关于申请同意光大财富医疗基金延期并签署补充协议的议 案》等文件。 每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 张明双） ...

山东华特达因健康股份有限公司 董事会秘书工作制度 第一章 总则 第一条 为进一步促进山东华特达因健康股份有限公司（以下简称"公司"） 规范运作，明确董事会秘书的职责权限，充分发挥董事会秘书的作用，依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《深圳证券交易所股票上市规则》（以下简称"《上 市规则》"）等有关法律、法规和部门规章以及《山东华特达因健康股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，制定本制度。 第二条 公司设董事会秘书一名，作为公司与深圳证券交易所之间的指定联 络人。董事会秘书是公司董事会聘任的高级管理人员，对公司和董事会负责。 第三条 董事会秘书应当遵守法律、行政法规、部门规章和《公司章程》的 规定，勤勉尽责地履行职责。 第二章 任职资格 第四条 董事会秘书应当具备履行职责所必需的相关专业知识和经验，具有 良好的职业道德和个人品德，并取得深圳证券交易所颁发的董事会秘书资格证书。 第五条 具有下列情形之一的人士不得担任董事会秘书： （一）有《公司法》第一百七十八条规定情形之一的； （二）被中国证监会采取不得担任上市公司 ...